Detalles de la búsqueda
1.
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer.
Breast Cancer Res Treat
; 195(3): 275-287, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35915198
2.
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 21(6): 763-775, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32353342
3.
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.
Oncologist
; 25(9): e1346-e1354, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32536013
4.
Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study.
Int J Gynecol Cancer
; 20(1): 75-81, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-20130506
5.
External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer.
BMC Cancer
; 7: 110, 2007 Jun 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-17598896
6.
Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.
Cancer Chemother Pharmacol
; 67(3): 519-25, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20461378
7.
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.
J Clin Oncol
; 29(34): 4498-504, 2011 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22025143
Resultados
1 -
7
de 7
1
Próxima >
>>